RoundOS
Pricing
Sign in
01 · Free data roomBuild, share and track important documents.
Data room analyticsDocument AnalyticsPitch Deck TrackingSecure sharingPermissionsNDA & agreementsWatermarkingVersionsBranding
View all Data Room features →
02 · AI Fundraising CRMRun the work between investor meetings.
Today & next movesFollow-upInvestor researchInvestor CRMInvestor updatesImports & sources
View all Operator features →
See it workingOpen a live roomWalk a real RoundOS room.
PricingSecurity
Deal rooms
StartupsVenture capitalM&A data roomInvestor relations
Beyond fundraising
Sales dealsBoard documentsDue diligenceReal estate
Fundraising
Fundraising hubPre-seedSeedSeries A
Learn
BlogFundingCustomer storiesInvestor room template
Compare
All alternativesBest free data roomsBest DocSend alternativesDigify alternativeiDeals alternative
Free tools & templates
Calculators and fundraising tools. No signup.
SAFE, dilution, runway, pipeline coverage, investor fit.
Sign inExploreData RoomAI Fundraising CRMPricingSecurityDocument AnalyticsPitch Deck TrackingData Room featuresData room analyticsSecure sharingPermissionsNDA & agreementsWatermarkingVersionsBrandingUse casesFundraising hubStartupsVenture capitalM&A data roomInvestor relationsSales dealsBoard documentsDue diligenceReal estatePre-seedSeedSeries AOperatorToday & next movesFollow-upInvestor researchInvestor CRMInvestor updatesImports & sourcesMoreCustomer storiesAll alternativesBest free data roomsInvestor room templateFree toolsBlogFundingIntegrations
Funding/Accro Bioscience/Series C

Accro Bioscience: Series C

Develops novel therapeutics for immune mediated diseases

Oct 4, 2026RoundOS

Accro Bioscience

Company profile and funding history

Sources

  1. prnewswire.com
Raised
$50M
Round
Series C
Announced
May 18, 2026
Sector
Biotech
Headquarters
United States

Investors

    All participants (6)
    • Cenova Capital
    • LAV
    • OrbiMed
    • Oriza Holdings
    • Shenzhen Capital Group
    • TCG Crossover

    More in Biotech

    AusperBio · Series CProFound Therapeutics · StrategicTransfyr · Seed
    BiotechUnited StatesHealthtechNorth AmericaSeries C+